Navigation Links
FDA Warns Against Bio-Identical Hormone Therapy
Date:1/9/2008

The menopause drugs are unregulated and could be dangerous, agency says

WEDNESDAY, Jan. 9 (HealthDay News) -- U.S. health officials warned Wednesday about so called "bio-identical hormone replacement therapy" (BHRT) drugs, an increasing popular alternative therapy among women with menopausal symptoms.

U.S. Food and Drug Administration officials said they've sent warning letters to seven pharmacies, most of them Internet-based, saying that claims touting the benefits of BHRT compounds aren't supported by medical evidence.

"FDA has issued warning letters to seven pharmacies that make false and misleading claims about their hormone therapy drugs and compound drugs containing estriol," Deborah M. Autor, director of the FDA's Office of Compliance in the Center for Drug Evaluation and Research, said during a Wednesday afternoon teleconference.

The FDA said the seven pharmacies improperly claim that their drugs, containing hormones such as estrogen, progesterone and estriol, are better than the agency's approved menopausal hormone therapy drugs and can prevent diseases such as Alzheimer's, stroke and cancers.

Autor noted the estriol has not been approved by the FDA for any use. In fact, it's illegal to put estriol in a compound unless the maker has a valid FDA investigational new drug application, she said.

The FDA is concerned that by making these false claims, the pharmacies are misleading patients and doctors about the risks and benefits of the BHRT drugs, Autor said.

The FDA said the BHRT therapies were becoming increasingly popular, following the 2002 Women's Health Initiative finding that traditional hormone replacement therapy could have dangerous side effects, including breast cancer, heart attack and stroke.

"Many pharmacy compounders use the term bio-identical to imply that their drugs are natural or natural to hormones made by the body," Autor said. "There is no creditable scientific support for this claim."

Also, while some of the pharmacies state their drugs are safer than FDA-approved hormone-replacement therapy medications, there's no evidence that they don't have the same risks and side effects as approved drugs, Autor said.

Pharmacies that don't address these violations run the risk of further enforcement, including injunctions and seizure of these drugs. However, the pharmacies can continue to make BHRT compounds as long as they don't contain estriol and don't make false claims, Autor said.

The FDA action isn't intended to target pharmacists who practice traditional pharmacy compounding -- combining or altering drug ingredients for an individual patient in response to a doctor's prescription -- and don't make false or misleading claims about compounded products, Autor said.

The FDA also received a petition from the drug maker Wyeth, of Madison, N.J., which asked the agency to take action against compounding pharmacy operations that produce compounded BHRT drugs. Others who have expressed concerns about these compounds include health-care providers and consumer groups, according to the FDA.

The seven pharmacies are Panorama Compounding Pharmacy of Lake Balboa, Calif.; Saint John's Medical Plaza Pharmacy of Santa Monica, Calif.; Murray Avenue Apothecary of Pittsburgh; Village Compounding Pharmacy of Houston; Pharmacy Compounding Specialties of Dallas; Reed's Compounding Pharmacy of Tucson, Ariz.; and Pacifica Pharmacy of Torrance, Calif.

Dr. Wulf Utian, executive director of the North American Menopause Society, said he supported the FDA's action.

"The FDA has done the right thing, and it's a pity it didn't happen sooner," Utian said. "We have no idea about the risks and benefits of these compounds, because they have not been subjected to the scrutiny the FDA gives to approved hormonal medications.

"If you are on a product that hasn't been FDA approved, you should see your doctor," he added. "If you have a good reason to be on hormones, you should ask to be converted to something that has undergone FDA scrutiny."

If a woman must take hormone replacement therapy to ease the symptoms of menopause, she should take the lowest possible dose for the shortest amount of time, the FDA said.

Phil Pylant, the owner of Village Compounding Pharmacy, said he couldn't figure out why his company was being singled out by the FDA. "I am one of 5,000 to 8,000 compounding pharmacies in the country that's doing the exact same thing -- including CVS and Walgreens -- and they all use the same drugs we use. Why they picked me out, I have no idea."

Pylant noted that all his compounds are made to order from a doctor's prescription. "We are order-takers, pharmacies cannot do anything without an authorized written prescription," he said. "If FDA had indicated that estriol was illegal, we wouldn't have used it.

"I don't make health claims," Pylant added. "The claims are being made by other people. There are books being written by physicians and people who use this stuff, and they make claims. If I'm claiming anything, it's because I'm a messenger. Why kill the messenger?"

More information

For more on bio-identical hormone therapy, visit the U.S. Food and Drug Administration.



SOURCES: Wulf Utian, M.D., Ph.D., executive director, North American Menopause Society, Cleveland; Phil Pylant, owner, Village Compounding Pharmacy, Houston; Jan. 9, 2008, teleconference with Deborah M. Autor, Esq., director, Office of Compliance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Health Department Warns Consumers of Home-Canned Soup Linked to Potter County Restaurant
2. Coalition of Caregivers Warns Congress of Danger to Oldest U.S. Seniors if Medicare Slashed
3. New research warns of the lack of specialization when judging individuals with mental disorders
4. Research warns that human papillomavirus might cause bladder cancer
5. PA Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Perry County Dairy
6. FDA Warns of Codeine Risk for Some Nursing Mothers
7. Cynosure Files Patent Infringement Lawsuit Against CoolTouch Inc.
8. Breast-Feeding Seems to Protect Against Some Allergies
9. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
10. Winemaking waste proves effective against disease-causing bacteria in early studies
11. Terriers Join Fight Against a Killer Disease in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Warns Against Bio-Identical Hormone Therapy
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics Inc. ... a modern CTMS workflow designed to seamlessly integrate and streamline the way researchers ... a single page, maximizing usability and improving efficiency significantly for users – a ...
(Date:1/19/2017)... ... January 19, 2017 , ... Students interested in video ... Awareness Scholarship competition., The winner will earn a $1,000 scholarship and have his or ... Feb. 1, and the deadline is May 31, with the winner announced on June ...
(Date:1/19/2017)... ... 2017 , ... Workrite Ergonomics announced this week the launch ... panel system was designed to deliver the ideal blend of acoustic and visual ... the visual privacy required to maintain concentration levels and increase productivity. The tranquility ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) officials today ... access to the Network’s programs and services in the greater Pittsburgh region. Starting January ... will be offered one for that same afternoon. , AHN is ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady ... services to communities throughout eastern Georgia, is embarking on a charity effort to ... disease kills more Americans every year than anything else, yet risk factors associated ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, ... anti-obesity drugs market is expected to grow at a CAGR ... CAGR of 38.7% in the second half of the forecast period. ... from 2016 to 2027. The market is estimated at $1,058 million ... ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
(Date:1/19/2017)... PALO ALTO, Calif. , Jan. 19, 2017 /PRNewswire/ ... scientific research, is excited to announce that the ... Project: Cancer Biology  (RP:CB) have been published in ... science, this project represents the first practical evaluation ... that result in reproducible studies. Unlike other assessments ...
Breaking Medicine Technology: